GLP1R and type 2 diabetes mellitus: Among the therapies recently introduced for treating T2DM, GLP-1 receptor agonists have been extensively studied because they stimulate insulin secretion and reduce glucagon secretion in a glucose-dependent manner, improving satiety and promoting weight loss [11,12].